TY - JOUR

T1 - Pathogenetic role and clinical significance of interleukin-1β in cancer

AU - Malkova, Anna M.

AU - Gubal, Anna R.

AU - Petrova, Anastasia L.

AU - Voronov, Elena

AU - Apte, Ron N.

AU - Semenov, Konstantin N.

AU - Sharoyko, Vladimir V.

N1 - Publisher Copyright: © 2022 John Wiley & Sons Ltd.

PY - 2022/4/24

Y1 - 2022/4/24

N2 - In recent years, pro-oncogenic mechanisms of the tumour microenvironment (ТМЕ) have been actively discussed. One of the main cytokines of the TМЕ is interleukin-1 beta (IL-1β), which exhibits proinflammatory properties. Some studies have shown an association between an increase in IL-1β levels and tumour progression. The purpose of this review is to analyse the pathogenic mechanisms induced by IL-1β in the TМЕ, as well as the diagnostic significance of the presence of IL-1β in patients with cancer and the efficacy of treatment with IL-1β inhibitors. According to the literature, IL-1β can induce an increase in tumour angiogenesis due to its effects on the differentiation of epithelial cells, pro-angiogenic molecule secretion and expression of adhesion molecules, thus increasing tumour growth and metastasis. IL-1β is also involved in the suppression of anti-tumour immune responses. The expression and secretion of IL-1β has been noted in various types of tumours. In some clinical studies, an elevated level of IL-1β was found to be associated with low efficacy of anti-cancer therapy and a poor prognosis. In most experimental and clinical studies, the use of IL-1β inhibitors contributed to a decrease in tumour mass and an increase in the response to anti-tumour drugs.

AB - In recent years, pro-oncogenic mechanisms of the tumour microenvironment (ТМЕ) have been actively discussed. One of the main cytokines of the TМЕ is interleukin-1 beta (IL-1β), which exhibits proinflammatory properties. Some studies have shown an association between an increase in IL-1β levels and tumour progression. The purpose of this review is to analyse the pathogenic mechanisms induced by IL-1β in the TМЕ, as well as the diagnostic significance of the presence of IL-1β in patients with cancer and the efficacy of treatment with IL-1β inhibitors. According to the literature, IL-1β can induce an increase in tumour angiogenesis due to its effects on the differentiation of epithelial cells, pro-angiogenic molecule secretion and expression of adhesion molecules, thus increasing tumour growth and metastasis. IL-1β is also involved in the suppression of anti-tumour immune responses. The expression and secretion of IL-1β has been noted in various types of tumours. In some clinical studies, an elevated level of IL-1β was found to be associated with low efficacy of anti-cancer therapy and a poor prognosis. In most experimental and clinical studies, the use of IL-1β inhibitors contributed to a decrease in tumour mass and an increase in the response to anti-tumour drugs.

KW - angiogenesis

KW - anti-cancer approaches

KW - cancer

KW - interleukin-1 beta (IL-1β)

KW - metastasis

KW - tumour microenvironment

KW - tumour progression

UR - http://www.scopus.com/inward/record.url?scp=85129392922&partnerID=8YFLogxK

UR - https://www.mendeley.com/catalogue/271494f5-5c56-3079-8ca1-b4650643e1bb/

U2 - 10.1111/imm.13486

DO - 10.1111/imm.13486

M3 - Review article

C2 - 35462425

AN - SCOPUS:85129392922

JO - Immunology

JF - Immunology

SN - 0019-2805

ER -